Navigation Links
Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
Date:4/17/2008

HOPKINTON, Mass., April 17 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) announced today that seven sites for the first stage of the ALTROPANE(R) Parkinson's or Essential Tremor - 2 (POET-2) Phase III clinical trial program are now open for patient enrollment. ALTROPANE molecular imaging agent is an investigational, diagnostic drug developed by Alseres to enable doctors to distinguish Parkinsonian Syndromes from non-Parkinsonian Syndromes in patients with tremor.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

The POET-2 program is a two-part registration program, the first part of which is a clinical study designed to enroll up to 90 subjects with tremor in seven U.S. medical centers. The objective is to acquire the set of ALTROPANE images which will be used to train the expert readers, a customary practice for clinical trials of molecular imaging agents. The second part of the planned POET-2 program will involve two concurrent, replicate, multi-center Phase III trials using the optimized ALTROPANE imaging protocol Alseres developed for commercial use.

"Both the investigators and institutions participating in this study are among the best in the country," stated Mark Hurtt, M.D., Alseres Chief Medical Officer. "With their help, we are committed to advancing ALTROPANE toward regulatory approval and commercialization to aid in the diagnosis of Parkinson's Disease or Essential Tremor. If these trials are successful and the drug is approved, we believe that ALTROPANE could be a highly-selective central nervous system diagnostic molecular imaging agent -- and a valuable tool to help clinicians make
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
2. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ... "Dental Consumables Market - Global Industry Analysis, Size, ... report to their offering. ... Dental consumables are products which are used on ... tooth restoration and in treatment of associated gingival ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion ... today announced that it has received commitments from ... $15 million of the Company,s common stock in ... dedicated health care fund. The Company ... pursuant to which the Company agreed to sell ...
(Date:1/15/2014)... -- BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ... Ltd (NYSE: TEVA ) and its subsidiaries ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... 2011 Hospira, Inc. (NYSE: HSP ), a ... that it will host a conference call to discuss its ... a.m. Central time. The company will release its ... open and the conference call. A live webcast ...
... DEL REY, Calif., April 4, 2011 Dr. Richard Merkin, ... official launch of the $3 million dollar Heritage Health Prize, ... celebrating the launch of the contest at the Data 2.0 ... interest in data mining and analytics to enter the $3 ...
Cached Medicine Technology:Heritage Provider Network Announces the Official Launch of the $3 million Dollar Heritage Health Prize 2Heritage Provider Network Announces the Official Launch of the $3 million Dollar Heritage Health Prize 3
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... California youth have,teamed up with doctors, teachers, law ... announcing its intent to stop selling,Rockstar 21, the ... Alcopops and Youth is calling on Anheuser Busch, ... to follow,Rockstar,s lead. Sold in brightly colored ...
... approach of winter season brings with it an increase ... the United States, fires and burns result in almost ... all age groups. , A new study conducted by ... at Nationwide Childrens Hospital, concludes that burn-associated injuries among ...
... Wis., Nov. 12 Shopko announced today the,appointment ... President and Chief,Merchandising Officer. Jones will be responsible ... of the regional mass retailer. Jones, career ... the,department store sector, mid-tier chain stores and big ...
... Pa., Nov. 12 ViroPharma Incorporated,(Nasdaq: VPHM ... Medicinal,Products (COMP) of the European Medicines Agency (EMEA) ... prevention of cytomegalovirus (CMV),disease in patients with impaired ... designed to promote the,development of drugs which may ...
... target immune system cells sent to kill them, study ... have uncovered a cache of molecular weapons that helps ... virulent. , Though more work must be done, the ... are so successful in causing infection and gives a ...
... FALLS, Idaho, Nov. 12 International,Isotopes Inc. (OTC ... quarter and nine months ending September 30, 2007. ... periods ended September,30, 2007, was $1,486,112 and $3,592,049 ... same periods in 2006. These numbers,represent an increase ...
Cached Medicine News:Health News:Youth and Community Groups Commend Rockstar for Taking 'The Buzz' out of its Energy Drinks 2Health News:Youth and Community Groups Commend Rockstar for Taking 'The Buzz' out of its Energy Drinks 3Health News:Burn injuries take devastating toll on nation's children 2Health News:ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM) 2Health News:ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM) 3Health News:ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM) 4Health News:Key to MRSA Virulence in Community Discovered 2Health News:Key to MRSA Virulence in Community Discovered 3Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2007 Financial Results 2Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2007 Financial Results 3Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2007 Financial Results 4
... TC-PLUS Solution tricompartmental total knee prosthesis stems ... arthroplasty. State-of-the-art design and manufacturing technologies have ... biomechanical function as well as a favorable ... insert to keep wear to a minimum. ...
... The TC-PLUS Solution tricompartmental total knee prosthesis ... knee arthroplasty. State-of-the-art design and manufacturing technologies ... optimum biomechanical function as well as a ... tibial insert to keep wear to a ...
... Knee System is a long term, quality ... Available in both posterior stabilized and anatomically ... System provides the flexibility needed to address ... ease of identification keeps the user in ...
... a long term, quality solution based on ... posterior stabilized and anatomically correct cruciate retaining ... flexibility needed to address patients' needs. In ... keeps the user in mind and promotes ...
Medicine Products: